<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03723447</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00053363</org_study_id>
    <nct_id>NCT03723447</nct_id>
  </id_info>
  <brief_title>Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)</brief_title>
  <acronym>TINGLE</acronym>
  <official_title>A Prospective Randomized Trial of Transversus Abdominis Plane (TAP) INtraoperative Block With Bupivacaine/Dexamethasone aGainst Liposomal Bupivacaine (Exparel®): the TINGLE Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative pain can pose significant challenges in the postoperative recovery of patients
      undergoing major colorectal surgery. Traditionally, opioids have played an important role in
      treating postoperative pain. It is well established that opioids are highly effective in
      relieving pain; however, opioids are associated with numerous side effects that include
      nausea, vomiting, constipation, ileus, bladder dysfunction, respiratory depression, pruritus,
      drowsiness, sedation, and allergic reaction. These opioid side effects, which range in
      severity, can significantly interfere with discharge home, particularly following colorectal
      surgery. Significant interest has grown for the use of guided regional anesthesia,
      specifically the use of the transversus abdominis plane (TAP) block to extend the
      post-operative analgesic window and ultimately limit opioid use. While bupivacaine
      formulations including a steroid has been shown to prolong the anesthetic effects of the
      regional field block, a new liposomal-depo formulation of bupivacaine (Exparel) has gained
      popularity and has additionally been shown to provide extended analgesia. Although promising
      data exists surrounding each modality, liposomal bupivacaine has not been studied in a
      well-powered clinical trial specifically in colorectal patients nor compared to a
      bupivacaine/steroid mixture.

      We are proposing a prospective randomized study of patients undergoing major laparoscopic
      colorectal surgery to compare the analgesic effects of a bupivacaine/steroid mixture versus
      liposomal bupivacaine (Exparel). We hypothesize that the liposomal formulation of bupivacaine
      will provide superior perioperative pain control at 48 hours post-operation measured by total
      consumed oral morphine equivalents. In addition, we will measure postoperative pain scores,
      time until ambulation, antiemetic use, length of postoperative hospital stay, postoperative
      ileus, and adverse events directly related or unrelated to TAP block in the 30-day
      postoperative period between the three groups.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 23, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Narcotic usage</measure>
    <time_frame>72 hours post-surgery</time_frame>
    <description>All narcotics used during the first 72 hours post-surgery periods will be converted to oral morphine equivalents and totaled</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-op Pain</measure>
    <time_frame>72 hours post-surgery</time_frame>
    <description>Visual pain scale recordings will be totaled and averaged during the first 72 hours post-surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel motility</measure>
    <time_frame>72 hours post-surgery</time_frame>
    <description>Time till flatus/ bowel movement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>30 days post-surgery</time_frame>
    <description>Time from operation until hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>30 days post-surgery</time_frame>
    <description>Medical or surgical complications measured by Clavien-Dindo classification</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Crohn Disease</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Gastrointestinal Cancer</condition>
  <condition>Gastrointestinal Disease</condition>
  <condition>Digestive System Disease</condition>
  <condition>Pain</condition>
  <condition>Pain, Neuropathic</condition>
  <condition>Intestinal Disease</condition>
  <arm_group>
    <arm_group_label>Bupivacaine/epinephrine/dexamethasone TAP block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For the bupivacaine/epinephrine/dexamethasone treatment arm, a standard weight-based dose of bupivacaine and epinephrine combined with 8mg dexamethasone will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liposomal bupivacaine TAP block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For the liposomal bupivacaine treatment arm, 266mg liposomal bupivacaine (Exparel) will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine</intervention_name>
    <description>Liposomal bupivacaine will be given during the bilateral laparoscopic-guided TAP block given to each patient intraoperatively.</description>
    <arm_group_label>Liposomal bupivacaine TAP block</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine/epinephrine/dexamethasone</intervention_name>
    <description>Bupivacaine/epinephrine/dexamethasone will be given during the bilateral laparoscopic-guided TAP block administered to each patient intraoperatively.</description>
    <arm_group_label>Bupivacaine/epinephrine/dexamethasone TAP block</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female

          2. Undergoing major laparoscopic colorectal procedure

          3. Willingness and ability to sign an informed consent document

          4. No allergies to anesthetic or analgesic medications

          5. ASA physical status Class I - III

          6. Aged 18-90 years

        Exclusion Criteria:

          1. Refusal to participate in the study

          2. Age &lt;18 or &gt; 90 years

          3. Pregnancy

          4. Contraindications to regional anesthetic including but not limited to:

               1. Patient refusal to regional field blockade

               2. Allergy

               3. Infection at the site of needle insertion

               4. Systemic infection

               5. Bleeding diathesis or coagulopathy (as diagnosed by history or laboratory
                  evaluation)

               6. Liver or renal disease (SCr &gt; 1.5)

          5. Chronic opioid use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 26, 2018</study_first_submitted>
  <study_first_submitted_qc>October 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2018</study_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Karen Zaghiyan</investigator_full_name>
    <investigator_title>Surgeon Investigator</investigator_title>
  </responsible_party>
  <keyword>transversus abdominis plane block</keyword>
  <keyword>tap block</keyword>
  <keyword>liposomal bupivacaine</keyword>
  <keyword>exparel</keyword>
  <keyword>dexamethasone</keyword>
  <keyword>colorectal surgery</keyword>
  <keyword>regional anesthesia</keyword>
  <keyword>bupivacaine</keyword>
  <keyword>surgery</keyword>
  <keyword>postoperative pain</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

